The Expression of Estrogen Receptor Subtypes in Prolactinomas and Their Relationship to Tumor Biological Behavior

Li, Chu Zhong; Gui, Song Bai; Zong, Xu; Zhang, Ya Zhuo

doi:10.1016/s0895-3988(15)30112-4

Cited by 24 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent meta-analysis showed that the sensitivity of MTBDR plus was 88.7% for the diagnosis of INH resistance for smear-positive TB patients, which was higher than in our findings 18 . However, several evaluations of new diagnostic tools in China revealed that the sensitivity for detecting resistance to INH was 80.3% for Genechip 8 and 80.2% for MTBDRplus 20 , respectively, similar to our observations. In addition, a molecular epidemiological study by Pang and other colleagues found that the combination mutations in the katG gene and the promoter of inhA gene only identify less than 75% of INH-resistant isolates in the MDR population in China, whereas 5.1% of MDR isolates only harbored point mutations in the oxyR-ahpC region 21 .…”

Section: Discussionsupporting

confidence: 90%

Evaluation of the MTBDRplus 2.0 assay for the detection of multidrug resistance among persons with presumptive pulmonary TB in China

Tan

Li²,

Wang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

We have conducted a multicenter study of the diagnostic accuracy of the MTBDRplus 2.0 assay in compared with conventional and molecular reference standard in four tuberculosis (TB)-specialized hospitals of China. A total of 5038 patients were enrolled in this study. The overall sensitivity of the assay for the diagnosis of TB was 92.7% [1723/1858, 95% confidence interval (95% CI): 91.5–93.9]. In smear-positive/culture-positive cases the sensitivity was 97.7% (995/1018, 95% CI: 96.6–98.6), whereas in smear-negative/culture-positive cases it was 86.7% (728/840, 95% CI: 84.2–88.9). The agreement rate between MTBDRplus 2.0 and Xpert MTB/RIF was 97.7% (1015/1039, 95% CI: 96.6–98.5) for smear-positive cases and 97.0% (3682/3794, 95% CI: 96.5–97.6) for smear-negative cases. As compared with phenotypic drug susceptibility testing, the MTBDRplus 2.0 correctly identified 298 of 315 patients (94.6%, 95% CI: 91.5–96.8) with rifampicin-resistance. As noted previously, isoniazid resistance is associated with many different mutations and consequently the sensitivity compared to phenotypic testing was lower (81.0%, 95% CI: 76.8–84.7). In conclusion, this assay is a rapid, accurate test in terms of increased sensitivity for detecting smear-negative TB patients, as well as an alternative for detecting both RIF and INH resistance in persons with presumptive TB, whereas the absence of a mutation in the specimens must be interpreted cautiously.

show abstract

Section: Discussionsupporting

confidence: 90%

Evaluation of the MTBDRplus 2.0 assay for the detection of multidrug resistance among persons with presumptive pulmonary TB in China

Tan

Li²,

Wang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Then, it has been suggested that surgical removal of the adenoma should be part of the patients counselling for the decision of the initial treatment, due to the low morbidity of this procedure, if performed by an experienced neurosurgeon [29]. In addition, the available of tumoral tissue may allow a detailed pathological analysis, for investigating both biomarkers of aggressiveness, as Ki67, p53, mitotic count, minichromosome maintenance 7 (MCM7) and estrogen receptors, and biomarkers of treatment response, as dopamine and somatostatin receptors [30][31][32][33]. In fact, a very detailed pathological analysis may facilitate the identi cation of cases with high risk of recurrence and may orient towards a personalized therapy, in particular in cases of di cult and aggressive prolactinomas [34].…”

Section: Discussionmentioning

confidence: 99%

Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors.

Mattogno

D’Alessandris

Chiloiro

et al. 2021

Preprint

View full text Add to dashboard Cite

Backgrounds: Prolactinomas represent a unique challenge for endocrinologists and neurosurgeons. Considering recent innovations in surgical practice, the authors aimed to investigate the best management for prolactinomas.Methods: A retrospective, cross-sectional and monocentric study was designed. Consecutive patients affected for prolactinomas were enrolled if treated with first line treatment with dopamine-agonist (DA) or trans-sphenoidal surgery (TS). Patients carried giant prolactinomas and those with a follow-up < 12 months were excluded. Results: 259 patients were enrolled. The first treatment was DA for 140 patients and TS for 119 cases. 146 of 249 patients (58.6%) needed a second therapy. Mean follow up was 102.2 months (12-438 months). Surgery highly impacted on the cure rate, in particular in females (p=0.0021) and in microprolactinomas (p=0.0020). Considering multivariate analysis, female gender and surgical treatment in the course of clinical history were the only independent positive predictors of cure at the end of 5 years follow-up (p=0.0016, p=0.0005). The evaluation of serum prolactin (24 hours after TS) revealed that 86.4% of patients with post-operative PRL≤10 ng/ml resulted cured at the end of follow-up (p< 0.0001).Conclusion: According to our experience, surgery allows a high cure rate of prolactinomas, particularly in females with microadenoma, with a good safety profile. TS for prolactinomas should be considered as concrete option, during the multidisciplinary evaluation, in centers of reference for pituitary diseases.

show abstract

“…In fact, in the most recent years, it was suggested that the trans-sphenoidal pituitary surgery should be considered an important part of the patients counselling for the decision of the initial treatment, according to the low morbidity of this procedure, if performed by an experienced neurosurgeon ( 27 ). In addition, the available of tumoral tissue may allow a detailed pathological analysis, for investigating both biomarkers of aggressiveness, as Ki67, p53, mitotic count, minichromosome maintenance 7 (MCM7) and estrogen receptors and both biomarkers of treatment response, as dopamine and somatostatin receptors ( [28][29][30][31]. In fact, a very detailed pathological analysis may facilitate the identi cation of cases with high risk of recurrence and may orient towards a personalized therapy, in particular in cases of di cult and aggressive PRL-omas.…”

Section: Discussionmentioning

confidence: 99%

Trans-Sphenoidal Surgery in Prolactin Secreting Pituitary Tumors: A Long-Term Referral Center Experience.

Mattogno

D’Alessandris

Chiloiro

et al. 2020

Preprint

View full text Add to dashboard Cite

Backgrounds: Prolactin secreting pituitary tumors (PRL-omas) represent a unique challenge for endocrinologists and neurosurgeons. Considering recent innovations in surgical, we aimed to investigate the best management for PRL-omas. Methods: A retrospective, cross-sectional and monocentric study was designed. Consecutive patients affected for PRL-omas were enrolled if treated with first line treatment with dopamine-agonist (DA) or trans-sphenoidal surgery (TSS). Patients carried giant PRL-omas and those with a follow-up < 12 months were excluded. Results: 259 patients were enrolled. The first treatment was DA for 140 patients and TSS for 119 cases. 146 of 249 patients (58.6%) needed a second therapy. Mean follow up was 102.2 months (12-438 months). Surgery highly impacted on the cure rate, in particular in females (p=0.0021) and in micro- PRL-omas (p=0.0020). Considering multivariate analysis, female gender and surgical treatment in the course of clinical history were the only independent positive predictors of cure at the end of 5 years follow-up (p=0.0016, p=0.0005). The evaluation of serum prolactin (24 hours after TSS) revealed that 86.4% of patients with post-operative PRL≤10 ng/ml resulted cured at the end of follow-up (p< 0.0001). Conclusion: According to our experience, surgery allows a higher cure rate of PRL-omas, in particular in females with micro-PRL-omas, with a good safety profile. TSS for PRL-oma should be considered as first line therapy, in the management of patients, during the multidisciplinary evaluation, in center of reference for pituitary diseases, in order guarantee a valid surgical outcome and a safety profile.

show abstract

The Expression of Estrogen Receptor Subtypes in Prolactinomas and Their Relationship to Tumor Biological Behavior

Cited by 24 publications

References 9 publications

Evaluation of the MTBDRplus 2.0 assay for the detection of multidrug resistance among persons with presumptive pulmonary TB in China

Evaluation of the MTBDRplus 2.0 assay for the detection of multidrug resistance among persons with presumptive pulmonary TB in China

Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors.

Trans-Sphenoidal Surgery in Prolactin Secreting Pituitary Tumors: A Long-Term Referral Center Experience.

Contact Info

Product

Resources

About